Sanjay Popat, Benjamin J. Solomon, Tom Stinchcombe, Geoffrey Liu, Gilberto Lopes, Melissa Lynne Johnson, Misako Nagasaka, Ece Cali Daylan, Christina S. Baik, James Thomas D'Olimpio, Tzu-chuan Jane Huang, Alexander I. Spira, Daniel Ernest Haggstrom, Ben C. Creelan, Kristina Kehrig, Junwu Shen, Rachel DeLaRosa, Viola Weijia Zhu, Alexander E. Drilon, Alice Tsang Shaw. "Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.tps8666